Hoffman Health Partners

12/31/2025

Reminder of our Holiday hours this week!

12/31/2025

We saw this post on Facebook and couldnt agree more!

Advice from an Urgent Care! Everyone is sick right now so stay out of folks faces.
RSV, Mycoplasma pneumonia, Flu A & B are going around. We’re seeing so many people at urgent care, daily. it’s so bad this year 😷
Treat symptomatically, these are all viruses, that can last UP TO 2-3weeks, especially that walking pneumonia, you can have a cough for months after. There’s no antibiotic treatment. Over the counter Mucinex DM, loosens all the mucus and thins it out, increase fluids, heavy on the water intake❗️use a humidifier if you have one. Take hot steamy showers, I recommend the v***r tablets, feels like heaven. Cough medicine for your cough (if you get rid of the mucus, you get rid of the cough) Tylenol/ibuprofen for your fever, pain, headaches, etc..
Also, sinus flushing (sinus suction for the littles) best thing you can do for the pressure headaches.
If you have a nebulizer, use it every 4-6 hours. If you don’t have the solution from the doctor, mix 2 cups of sterile water (bottled or boiled) with 1 tsp of salt, helps break up all that mucus in your lungs, chest, head ❗️

I copy and pasted from a friend this is great advice!!

12/17/2025

Holiday hours over the next 2 weeks.

11/21/2025

The office will be Closed on November 27 & 28 for the Thanksgiving Holiday. Be safe & enjoy your families 🦃

11/13/2025

SPOTS ARE STILL AVAIABLE TODAY UNTIL 2PM!

The newest Colon Cancer Screeing is here! We are excited to announce we will be hosting a Shield Drawing Day on November 13th at the office. To be eligible for Shield you must be age 45 - 85 and have Tricare, Medicare, or a Medicare Advantage insurance. Call the office to get place on the list 5702684096.

The term "shield colon cancer test" refers to the Guardant Shield test, a blood-based screening option for colorectal cancer. It is manufactured by Guardant Health and was approved by the FDA in July 2024 for average-risk adults aged 45 and older.
How the Guardant Shield test works
The test is a liquid biopsy that detects cancer-related alterations in cell-free DNA (cfDNA), which are released from tumors into the bloodstream.
A healthcare provider performs a simple blood draw using the Guardant Shield Blood Collection Kit.
The blood sample is sent to a lab for analysis.
The lab analyzes the cfDNA for genomic mutations, methylation, and fragmentation patterns that are associated with colorectal cancer.
The results are reported as either "positive" or "negative".
Test results and their meaning
Positive result: A positive result means a signal associated with colorectal cancer was detected, but it does not confirm a cancer diagnosis. A follow-up colonoscopy is required to investigate the result. The test has a 10% false-positive rate, meaning 1 in 10 average-risk people without advanced neoplasia will incorrectly receive a positive result.
Negative result: A negative result means a signal was not detected, but it does not guarantee the absence of colorectal cancer or advanced precancerous polyps. Ongoing screening is still necessary. The test missed 17% of colorectal cancer cases in clinical trials, particularly early-stage cancers.

11/12/2025

TOMORROW IS THE DAY! Blood draws are being done 10am - 2pm. Please call now to get placed on the list! If you have no interest in a Colonoscopy or as our patients say " p**p in a box" Cologuard this is a great opportunity to still screen for Colorectal Cancer.

The newest Colon Cancer Screeing is here! We are excited to announce we will be hosting a Shield Drawing Day on November 13th at the office. To be eligible for Shield you must be age 45 - 85 and have Tricare, Medicare, or a Medicare Advantage insurance. Call the office to get place on the list 5702684096.

The term "shield colon cancer test" refers to the Guardant Shield test, a blood-based screening option for colorectal cancer. It is manufactured by Guardant Health and was approved by the FDA in July 2024 for average-risk adults aged 45 and older.
How the Guardant Shield test works
The test is a liquid biopsy that detects cancer-related alterations in cell-free DNA (cfDNA), which are released from tumors into the bloodstream.
A healthcare provider performs a simple blood draw using the Guardant Shield Blood Collection Kit.
The blood sample is sent to a lab for analysis.
The lab analyzes the cfDNA for genomic mutations, methylation, and fragmentation patterns that are associated with colorectal cancer.
The results are reported as either "positive" or "negative".
Test results and their meaning
Positive result: A positive result means a signal associated with colorectal cancer was detected, but it does not confirm a cancer diagnosis. A follow-up colonoscopy is required to investigate the result. The test has a 10% false-positive rate, meaning 1 in 10 average-risk people without advanced neoplasia will incorrectly receive a positive result.
Negative result: A negative result means a signal was not detected, but it does not guarantee the absence of colorectal cancer or advanced precancerous polyps. Ongoing screening is still necessary. The test missed 17% of colorectal cancer cases in clinical trials, particularly early-stage cancers.

10/30/2025

The newest Colon Cancer Screeing is here! We are excited to announce we will be hosting a Shield Drawing Day on November 13th at the office. To be eligible for Shield you must be age 45 - 85 and have Tricare, Medicare, or a Medicare Advantage insurance. Call the office to get place on the list 5702684096.

The term "shield colon cancer test" refers to the Guardant Shield test, a blood-based screening option for colorectal cancer. It is manufactured by Guardant Health and was approved by the FDA in July 2024 for average-risk adults aged 45 and older.
How the Guardant Shield test works
The test is a liquid biopsy that detects cancer-related alterations in cell-free DNA (cfDNA), which are released from tumors into the bloodstream.
A healthcare provider performs a simple blood draw using the Guardant Shield Blood Collection Kit.
The blood sample is sent to a lab for analysis.
The lab analyzes the cfDNA for genomic mutations, methylation, and fragmentation patterns that are associated with colorectal cancer.
The results are reported as either "positive" or "negative".
Test results and their meaning
Positive result: A positive result means a signal associated with colorectal cancer was detected, but it does not confirm a cancer diagnosis. A follow-up colonoscopy is required to investigate the result. The test has a 10% false-positive rate, meaning 1 in 10 average-risk people without advanced neoplasia will incorrectly receive a positive result.
Negative result: A negative result means a signal was not detected, but it does not guarantee the absence of colorectal cancer or advanced precancerous polyps. Ongoing screening is still necessary. The test missed 17% of colorectal cancer cases in clinical trials, particularly early-stage cancers.

09/18/2025

These guys from M-R Maintenance Rentals have been busy all day tearing it up! The repaving project is moving along nicely.

To the patients that have been understanding as to why the office is closed we would like to say THANK YOU! We definitely need to spread kidness in this world!

09/18/2025

Reminder the office is closed for in-person visits. We are available by phone only.

09/16/2025

ATTENTION PATIENTS!

09/12/2025

The lab is closed today please go to the hospital for all blood draws